Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to HSP90 inhibitor by Anat Zimmer et al.
RESEARCH ARTICLE Open Access
Dynamic proteomics reveals bimodal
protein dynamics of cancer cells in
response to HSP90 inhibitor
Anat Zimmer, Shlomit Amar-Farkash, Tamar Danon and Uri Alon*
Abstract
Background: Drugs often kill some cancer cells while others survive. This stochastic outcome is seen even in clonal
cells grown under the same conditions. Understanding the molecular reasons for this stochastic outcome is a
current challenge, which requires studying the proteome at the single cell level over time. In a previous study we
used dynamic proteomics to study the response of cancer cells to a DNA damaging drug, camptothecin. Several
proteins showed bimodal dynamics: they rose in some cells and decreased in others, in a way that correlated with
eventual cell fate: death or survival. Here we ask whether bimodality is a special case for camptothecin, or whether
it occurs for other drugs as well. To address this, we tested a second drug with a different mechanism of action, an
HSP90 inhibitor. We used dynamic proteomics to follow 100 proteins in space and time, endogenously tagged in
their native chromosomal location in individual living human lung-cancer cells, following drug administration.
Results: We find bimodal dynamics for a quarter of the proteins. In some cells these proteins strongly rise in level
about 12 h after treatment, but in other cells their level drops or remains constant. The proteins which rise in
surviving cells included anti-apoptotic factors such as DDX5, and cell cycle regulators such as RFC1. The proteins
that rise in cells that eventually die include pro-apoptotic factors such as APAF1. The two drugs shared some
aspects in their single-cell response, including 7 of the bimodal proteins and translocation of oxidative response
proteins to the nucleus, but differed in other aspects, with HSP90i showing more bimodal proteins. Moreover, the
cell cycle phase at drug administration impacted the probability to die from HSP90i but not camptothecin.
Conclusions: Single-cell dynamic proteomics reveals sub-populations of cells within a clonal cell line with different
protein dynamics in response to a drug. These different dynamics correlate with cell survival or death. Bimodal
proteins which correlate with cell fate may be potential drug targets to enhance the effects of therapy.
Background
Cancer drugs often kill some cells while other cells sur-
vive [1–5]. This stochastic outcome occurs even in
clonal cells that are under identical conditions such as
sister cells on the same plate. This stochastic resistance
is non-genetic: The surviving cells, when re-plated, often
give rise to populations that again show the same frac-
tion of death versus survival in response to the drug [4,
6–8]. Inherited resistance evolves much slower, and usu-
ally occurs only after many such passages [3, 6, 9, 10].
The stochastic survival of cells may be one reason that
cancer drugs do not always succeed in eliminating
tumors, and understanding how some cells survive is
therefore a pressing need.
In order to understand the molecular basis for the sto-
chastic outcome of a drug, one needs to view the prote-
ome in individual cells over time. Most existing proteomic
methods average over millions of cells and therefore mask
single-cell effects [1, 11]. Techniques for single-cell ana-
lysis based on immunostaining [12, 13] or transcriptomics
[5] require fixing the cells and thus preclude studying the
dynamics and eventual fate of each cell.
We have previously established a dynamic proteomics
approach that addresses these issues and is able to fol-
low proteins in single living human cancer cells over
time. Dynamic proteomics is based on a library of cancer
cell clones. Each clone expresses a full length tagged
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protein from its endogenous chromosomal locus [14–
16]. We used this method to study the response of cells
to the chemotherapy drug camptothecin (CPT) [2]. CPT
is a topoisomerase poison which causes DNA damage
[17] in dividing cells. Survival and death of different cells
was found not to be due to cell-cycle differences. In-
stead, several proteins were found with different dynam-
ics in individual cells, which correlated with cell fate.
These proteins were called bimodal proteins: their level
rose 20 h after CPT treatment in some cells, but de-
creased in other cells. Two proteins rose primarily in
cells that survived, DDX5 and RFC1. Knocking down
these proteins enhanced killing by CPT, suggesting a
causal effect [2].
Here we ask whether bimodality of protein dynamics
is specific to CPT, or whether it occurs also for another
drug. For this purpose we used dynamic proteomics to
analyze the response to a drug with a different mechan-
ism of action, an HSP90 inhibitor (HSP90i). The HSP90i
class of drugs inhibits the chaperone HSP90 and there-
fore interferes with protein degradation, which is
thought to affect cancer cells more strongly than other
cells [18–22].
We used dynamic proteomics to study how cells
respond to an HSP90 inhibitor. We followed 100
proteins in space and time in living cancer cells fol-
lowing HSP90i treatment. We find 16 bimodal pro-
teins whose protein dynamics are correlated with
cell fate (survival/death). Seven of these were bi-
modal also in the previous CPT study. This indicates
the formation of subpopulations of cells 12 h post
treatments within a clonal cell line, long before
death begins to at about 20 h. Unlike CPT, we find
that HSP90i efficacy is correlated with the cell cycle.
We further find localization changes of oxidative-
stress response proteins which indicate that oxidative
stress response is activated about 20 h after treat-
ment. The dynamic proteomic approach thus sug-
gests that bimodality may be a widespread response
of cells to anti-cancer drugs, indicating that subpop-
ulations with differential survival are induced by the
drug many hours before death occurs.
Methods
Fluorescently-tagged protein clone library
The clones in this study were taken from the LARC li-
brary, in which proteins were fluorescently-tagged in
their native locus and under their native regulation by
CD-tagging as previously described [2, 23]. Briefly,
H1299 (non-small cell lung carcinoma commercial cell
line) cells were double tagged using the CD-tagging
method, such that all clones contains a red fluorescent
mCherry protein fused to a protein that is brighter in
the nucleus and dimmer in the cytoplasm and is used
for automated image analysis, and each clone expresses
a yellow tag (eYFP or Venus) fused to the protein of
interest. Each clone in the library originated from a sin-
gle cell obtained by sorting for YFP fluorescence.
The H1299 cells that used to establish the LARC li-
brary originated from a commercial cell line, as de-
scribed in Cohen et al. [2].
Clone selection
For this study we chose a subset of clones from the
LARC library. Clones were selected to provide coverage
of different cellular pathways (such as: cell division,
apoptosis, cell signaling), protein functions (such as: kin-
ase, phosphatase, protease) and localization (such as: nu-
clei, nucleoli, cytoplasm, membrane). We chose 14
proteins which were found to be bimodal in the previous
study of CPT (Table 1).
Tissue Culture Media
Cells were grown in RPMI 1640 supplied with (+) L-
Glutamine (GIBCO, catalog number 21875) medium
supplemented with 10% Fetal Calf Serum (certified
fetal bovine serum, membrane filtered, Biological In-
dustries, catalog number 04-001-1A) and 0.05%
Penicillin-Streptomycin antibiotics (Biological Indus-
tries, catalog number 03-031-1B), in incubators at
37 °C and 8% CO2.
Drug addition
HSP90 inhibitor (MSC1972516 (EMD-614684)) [20],
was dissolved in DMSO (hybri-max, D2650 Sigma)
giving a stock solution of 1 mM. The drug was diluted
to a final concentration of 1 μM by 1:1000 dilution in
transparent growth medium (RPMI 1640, 0.05%
Penicillin-Streptomycin antibiotics, 10% FCS, with L-
Glutamine, lacking riboflavin and phenol red, Bet
Haemek, Biological Industries Cat. No. 06-1100-26-
1A). Cells were grown in 96-well plates (7 × 103 cells
per well) with normal (red) RPMI medium. Before
each experiment, normal (red) RPMI medium was re-
placed by transparent RPMI 1640 (lacking riboflavin
and phenol red to decrease medium fluorescence) with
the desired drug (volume of 200ul per well). HGF
(Hepatocyte Growth factor, Recombinant Human
HGF, Catalog Number: 294-HGN, reconstituted at
50 μg/mL in sterile PBS containing 0.1% human or bo-
vine serum albumin) was added at a final concentra-
tion of 100 ng/ml.
Time-lapse microscopy
Time-lapse movies were obtained at 20× magnification,
in IDEA Bio-Medical Ltd. WiScan system which in-
cludes Olympus inverted fluorescence microscope
(modified IX71), live cell environmental incubators
Zimmer et al. BMC Systems Biology  (2017) 11:33 Page 2 of 11
Table 1 list of Proteins used in this study, functional annotation based on Genecards [http://www.genecards.org/], and dynamic
profile classification. Down–decrease in time, Down-up decrease in first 12 h followed by increase, up–increase over time
Protein name Description Dynamics
CKS2 CDC28 protein kinase, down regulated by p53, G1/S phase transition Up
BAG1 blocks apoptosis, enhances anti-apoptotic effects of BCL2, Inhibits chaperone activity
VPS26A retromer complex, retrieve lysosomal enzyme receptors from endosomes to the Golgi
H2AFV H2A histone protein, nucleosome assembly Down-up
UBE2K ubiquitin enzyme E2, p53 degradation, NRF2 Oxidative Stress Response
CACYBP ubiquitin degradation, beta-catenin degradation, positive regulation of DNA replication
RAB11A RAS oncogene, membrane delivery during cytokinesis, protein transport, endocytosis
TXN Upregulate JUN & NFkB, apoptosis
STMN1 destabilizing microtubules, mitotic spindle organization, activated by ERK
STK24 serine/threonine kinase, apoptosis, upstream (MAPK) cascade
RPS3A ribosomal protein, translation, induction of apoptosis (BCL2 regulation)
TXNRD1 response to oxidative stress, induces actin &tubulin polymerization, cell death
FSCN1 actin-bundling protein, cell motility & migration, cell proliferation
RBX1 E3 ubiquitin ligase, cell cycle progression, DNA repair
SUMO1 ubiquitin-like, DNA repair, upregulate P53, nuclear transport, apoptosis, protein stability
PAK2 p21 activated kinase, cytoskeleton reorganization, anti apoptosis
TBCA tubulin folding, stabilizing beta-tubulin
SPCS1 proteolysis, metabolic process, removes signal peptides from proteins in the ER
PRKAR2A kinase, cAMP-dependent, lipid&glucose metabolism, signaling of GPCR, anti apoptosis
CALM2 regulates the centrosome cycle and cytokinesis
MAPK1 Proliferation, transformation- also known as ERK2, kinase
IL3RA interleukin 3 receptor, Immune response IL-3, Apoptosis, Jak-STAT signaling pathway
PLEC1 intermediate filaments with MT & microfilaments, apoptosis, cell junction assembly
PTPN11 Phosphatase, an upstream activator of Src & ras, Proliferation, transformation
BAG2 BCL2-associated, Inhibits chaperones, apoptosis
PCMTD2 protein modification, protein-L-isoaspartate(D-aspartate)O-methyltransferase domain
VIL2 ezrin, intermediate between the PM and actin cytoskeleton, activate MET with CD44
APAF1 initiates apoptosis
MAP2K2 kinase, Activates the ERK1 and ERK2, Proliferation, transformation
RFC1 replication & repair factor, subunit DNA polymerase, S phase of mitotic cell cycle
TJP1 tight junction protein, apoptosis
EEF2 elongation factor, protein synthesis
DDX5 RNA helicases, splicing, cellular growth and division, P53 TF
PSMB4 proteasome, cell cycle checkpoint
MAPKAP1 mTORC2 Subunit, regulates cell growth & survival, regulate the actin cytoskeleton
ENO1 Enolase, glycolysis, growth control, hypoxia tolerance, receptor, down regulate myc
PBX3 Transcriptional activator that binds the sequence 5-ATCAATCAA-3
RPL11 ribosomal protein L11, rRNA processing, translation
LMNA nuclear membrane fibrous, apoptosis, During mitosis disassembled, nuclear stability
CDKN3 cell cycle arrest
RPS3 ribosomal protein, translation, induction of apoptosis, repair UV-induced DNA damage
FBL snRNP, pre-r/tRNA processing, physical interaction with DDX5, coexpress with NCL
AKAP8L nuclear envelope breakdown & chromatin condensation. initiation of DNA replication
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maintaining 37 °C (37-2 digital and Heating unit, PeCon,
Germany, Leica #15531719), humidity and 8% CO2
(PeCon, GmbH, Germany #0506.000-230, Leica
#11521733) and automated stage movement control
(Corvus, ITK, GmbH, Germany); the stage was sur-
rounded by a custom enclosure to maintain constant
temperature, CO2 concentration, and humidity. Transmit-
ted and fluorescent light paths were controlled by elec-
tronic shutters (Uniblitz, model VMM-D1, Rochester, NY);
Fluorescent light sources were Short ARC Lamp HXP R
120w/45C VIS (OSRAM, Germany). iXon (Andor technol-
ogy) cooled 14 bit CCD camera was used. The filters used
were from Chroma Technology: Olympus Dual channel di-
chroic with excitation and emission filters mounted on fast
filter wheels (Chroma set 490/20x, 577/25x, 535/30 m,
632/60 m).
Cells were visualized in 96-well optical glass-bottom
plates (96 well optical CVG sterile w/lid Black, catalog
number 164588 Thermo scientific nunc) coated with
10 μM fibronectin 0.1% (solution from bovine plasma,
Sigma, Cat. No. F1141) diluted 1:100 in Dulbecco’s Phos-
phate Buffered Saline, PBS (Sigma, Cat. No. D8537). For
each well, time-lapse movies were obtained at four fields
of view. Each movie was taken for 2 days with 30 min
resolution (100 time points). Each time point included
three frames: a transmitted light image, and two fluores-
cent channels (red and yellow). In the present study we
use the first 24 h of each movie.
Table 1 list of Proteins used in this study, functional annotation based on Genecards [http://www.genecards.org/], and dynamic
profile classification. Down–decrease in time, Down-up decrease in first 12 h followed by increase, up–increase over time (Continued)
PSMC4 proteasome cell cycle checkpoint Down
HDAC2 histone deacetylase, cell growth arrest, differentiation and death
PSMB7 proteasome cell cycle checkpoint
PDCD5 induction of apoptosis
RRAS Regulates the organization of the actin cytoskeleton, RAS related, activates RAF
DNMT1 CpG methylation, activated by JUN, STAT3, involved in P53 AKT paths
K-alpha-1 tubulin, alpha 1b
HMGA2 negative transcription regulation, chromatin organization, G1/S and G2/M transitions
ARL3 cytokinesis and cilia signaling, microtubule binding, intracellular protein transport
VCL (F-actin)-binding protein, cell-matrix & cell-cell adhesion, cell morphology, locomotion
CD44 MET activation, wound healing, inflammatory response, cell adhesion
PSMA1 proteasome, cell cycle checkpoint, Immune response
PGK1 phosphoglycerate kinase, glycolytic enzyme
ILF2 immune response
RPL22 ribosomal protein, component of the 60S subunit
PPP1R2 carbohydrate metabolic process, phosphatase
PKN1 JUN kinase activity, regulation of the actin cytoskeleton, TF
HMGA1 regulation of transcription
PTTG1 protein import into nucleus
NPM1 chaperoning, histone assembly, cell proliferation, regulation of p53/TP53, ARF
NASP transporting histones into the nucleus, cell proliferation
PFDN5 chaperone
HAT1 internal protein A.A. acetylation, DNA packaging, HMGB1 signaling, DNA repair
STK4 pro apoptosis regulator
RTN4 pro apoptosis regulator
PAWR PRKC, pro apoptosis regulator
SLBP histone mRNA 3-end processing, mRNA export from nucleus
CFLAR CASP8 pro apoptosis gene
YT521 RNA splicing (May be part of a signaling and alternative splicing)
ANXA2 Calcium-regulated membrane-binding protein, signal transduction
DNCH1 Microtubule molecular motors-cytoplasmatic.
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Image Analysis of Time-Lapse Movies
The image analysis software described in Cohen et al.
[2] was used to analyze the time lapse movies in this
study. The main steps in this software include back-
ground correction (flat field and background subtrac-
tion), segmentation, cell tracking, and automated
identification of cell phenotypes (mitosis and cell death).
Global image threshold (Otsu, 1979) followed by water-
shed segmentation was used to segment the nuclei and
cytoplasm based on the red fluorescent images of the
red tagged protein found in all clones. Tracking was per-
formed by analysis of the movie from end to start and
linking of each segmented cell to the cell in the previous
image with the closest centroid, and other attributes like
protein levels. Automated cell death identification algo-
rithm utilized the morphological changes such as enve-
lope breakdown, and cell roundness correlated with
dying cells, and cells that undergo mitosis.
Definition of clones with bimodal dynamics
For every clone, we calculated the slopes between
every two time-points starting from t0 = 12 h after
drug administration until t1 = 20 h after drug adminis-
tration (total of 17 time points). We calculated for
every cell the mean and median of the slopes between
t0 and t1. Mean and median calculation showed simi-
lar results. Next we divided the cells in the clone into
two groups: cells that had a positive slope on aver-
age–meaning that the protein level increased, and
cells that had negative slope on average–meaning a
decrease in protein level. We removed clones in
which there were fewer than 10 cells in at least one
of the two groups, or in which the movie quality was
judged to be insufficient for analysis, remaining with
75 clones. We calculated the distribution of mean
slopes in each group (positive and negative mean
slope), and applied three tests for the null hypothesis
H0 that these two groups are drawn from the same
distribution: t-test, KS test and the nonparametric
Mann Whitney test. To control for multiple hypoth-
esis testing we applied the Benjaminy-Hochberg pro-
cedure with FDR = 0.1 to the results from all three
tests. This result in a list of 25 proteins in which H0
can be rejected (p < 0.05 in all three tests).
Bimodal dynamics and cell fate
We analyzed the 25 bimodal clones in terms of cell sur-
vival or death at 24 h. We divided the cells into two
groups according to the fate of the cells, compared the
slope distribution in these two groups, as described in
the section above. We find that for 16 clones, cell fate
significantly differed in the two groups (t-test, KS and
MW tests, p < 0.05, Benjamini Hochberg corrected with
FDR = 0.1).
Fig. 1 Workflow of dynamic proteomics in response to Hsp90 inhibitor drug: We used the LARC library of over 1000 H1299 cancer cell clones; in each
clone a protein is tagged fluorescently at its natural locus using exon tagging. We selected 100 proteins in diverse pathways and functions, and
assayed their dynamics in the presence of the drug, as well as in a control conditions. Time lapse movies over 20 h were conducted in 96-well format.
Automated image analysis captured the protein dynamics at the individual cell level, as well as mitosis and death events for each cell
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Results
To study how cells respond to an HSP90 inhibitor we
used dynamic proteomics. We measured the dynamics
of 100 proteins involved in a wide range of cellular func-
tions including signaling, growth and death, in response
to 1 uM of an Hsp90 inhibitor (Merc Serrono
MSC1972516) (proteins listed in Table 1). Cell death oc-
curred 15 h+/−3 after drug addition. Protein dynamics
were assayed using clones from the LARC library, de-
scribed in [2]. In these clones of the H1299 lung-cancer
cell line, proteins were tagged with YFP at their en-
dogenous chromosomal location (Fig. 1) using a CD-
tagging approach. Previous work showed that the clones
express full length tagged proteins from their native
locus with intact regulatory sequences. All clones also
express red fluorescent proteins that aid fully-automated
image analysis. Dynamics of protein level at a resolution
of 30 min were examined for 24 h after drug addition in
96-well plates in a dedicated fluorescence microscopy
system with controlled CO2 and temperature. Protein
YFP level and localization, as well as cell mitosis and
death events were automatically tracked and quantitated
for hundreds of individual cells per clone as described
[2] (Fig. 1). Protein YFP levels averaged over all cells
showed diverse dynamics with most proteins dropping
in levels on average and several other rising at late times
(Fig. 2). Such dynamics that are averaged over all cells
mask single cell-effects, to which we now turn.
A quarter of the proteins show bimodal behavior,
decaying in some cells and increasing in others, in a way
that correlates with cell fate
We studied the dynamics of the proteins at the individ-
ual cell level. We used the criteria of [2] to define bi-
modal dynamics: we computed the rate of accumulation
of YFP protein level for each cell defined by the slope of
the YFP curve over time. We separated the cells into
two groups, with positive and negative slopes. Bimodal
proteins were proteins from which the slope distribution
of the two groups was significantly different as judged by
using statistical tests (see Methods, t-test results shown
in Table 2). We find that 25 out of 100 proteins (listed
Fig. 2 Dynamics of all proteins as a function of time after addition of the Hsp90 inhibitor. Protein dynamics was averaged over all cells, centered
and normalized to mean zero and standard deviation one. Red denotes high relative levels and blue–low levels. Ordering of proteins is based on
clustering the dynamics using Matlab
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in Table 2) displayed a bi-modal response to HSP90i
with expression increasing in some cells but decreasing
in other cells 12 h after drug addition (Fig. 3).
For 16 out of the 25 bimodal proteins the protein dy-
namics correlated with cell fate (death or survival at the
end of the experiment). These proteins and their func-
tion are listed in Table 2. For 12 proteins, such as
STMN1, a protein important for mitosis spindle
organization, cells that increase the protein level are
preferentially killed (p = 7e−15). Many of these proteins
are not naturally associated with cell death, including
proteins involved in mitosis and in anti-apoptotic func-
tions. The increase of 4 proteins correlated with cell sur-
vival, including DDX5 and RCF1. For 9 of the bimodal
proteins we found no significant correlation with cell
death or cell survival.
Six of the bimodal proteins, DDX5, RFC1, BAG1,
BAG2, SPCS1, CALM2 and PCMTD2 were previously
identified as bimodal also for CPT. The other 18 bi-
modal proteins found here were not bimodal in CPT,
suggesting that the stochastic mechanisms in the re-
sponse to the two drugs have only partial overlap.
Cells that attempt mitosis 12 h or more after drug
addition are preferentially killed
We next asked whether the cell-cycle phase at the mo-
ment of drug administration affects cell survival. We
automatically detected mitosis events as described [2],
using morphological changes of cells, primarily cell
rounding (see Methods) [2, 14, 16, 24]. We find that
cells that attempt mitosis 12 h or more after drug ad-
ministration were not able to complete cell division and
were preferentially killed (82%), whereas cells that show
the morphological correlate of mitosis in the first 12 h
were able to complete mitosis and were less frequently
killed (35%), Fig. 4. This finding suggests that HSP90i ef-
fect depends on the cell-cycle stage of the cells. In con-
trast CPT showed no dependence on cell cycle stage,
highlighting another difference between the drugs at the
level of individual cell responses.
Table 2 Bimodal Proteins, their functional annotation and their correlation to cell fate. Annotation is based on Genecards [http://
www.genecards.org/]
Protein name Description Bimodal correlation to death P-value
APAF1 initiates apoptosis Increase correlates with death 3E-13
BAG1 blocks apoptosis, enhances anti-apoptotic effects of BCL2, Inhibits chaperone activity 8E-07
BAG2 BCL2-associated, Inhibits chaperones, apoptosis 2E-03
CACYBP ubiquitin degradation, beta-catenin degradation, positive regulation of DNA replication 3E-08
CALM2 regulates the centrosome cycle and cytokinesis 3E-04
CKS2 CDC28 protein kinase, down regulated by p53, G1/S phase transition 2E-05
IL3RA interleukin 3 receptor, Immune response IL-3, Apoptosis, Jak-STAT signaling pathway 5E-49
RAB11A RAS oncogene, membrane delivery during cytokinesis, protein transport, endocytosis 2E-08
RBX1 E3 ubiquitin ligase, cell cycle progression, DNA repair 2E-02
STK24 serine/threonine kinase, apoptosis, upstream (MAPK) cascade 2E-02
STMN1 destabilizing microtubules, mitotic spindle organization, activated by ERK 7E-15
TXN Upregulate JUN & NFkB, apoptosis 8E-27
DDX5 RNA helicases, splicing, cellular growth and division, P53 TF Increase correlates with survival 1E-05
MAP2K2 kinase, Activates the ERK1 and ERK2, Proliferation, transformation 2E-05
RFC1 replication & repair factor, subunit DNA polymerase, S phase of mitotic cell cycle 9E-08
TBCA tubulin folding, stabilizing beta-tubulin 2E-02
H2AFV H2A histone protein, nucleosome assembly no correlation with death 5E-04
LMNA nuclear membrane fibrous, apoptosis, During mitosis disassembled, nuclear stability 5E-58
PAK2 p21 activated kinase, cytoskeleton reorganization, anti apoptosis 2E-10
PCMTD2 protein modification, protein-L-isoaspartate(D-aspartate)O-methyltransferase domain 7E-04
PLEC1 intermediate filaments with MT & microfilaments, apoptosis, cell junction assembly 1E-04
PRKAR2A kinase, cAMP-dependent, lipid&glucose metabolism, signaling of GPCR, anti apoptosis 9E-05
PTPN11 Phosphatase, an upstream activator of Src & ras, Proliferation, transformation 1E-02
SPCS1 proteolysis, metabolic process, removes signal peptides from proteins in the ER 3E-19
TJP1 tight junction protein, apoptosis 2E-02





Fig. 3 (See legend on next page.)
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Oxidative stress proteins increase in levels and enter the
nucleus after drug addition
The dynamic proteomic approach also allows detection
of localization changes in response to drugs. We observe
translocations of thioredoxin (TXN) and thioredoxin re-
ductase (TrxR), which show nuclear entry after 20 h
(Fig. 5). This translocation occurs upon oxidative stress
response [25–27]. A similar translocation of these two
proteins occurred also for CPT [2]. Oxidative stress re-
sponse is an off-target effect for these two drugs.
Discussion
We asked whether bimodal protein dynamics, which
were found for CPT, also occur for another drug with a
different mechanism of action. We therefore used the
dynamic proteomics approach to study how individual
cancer cells respond to an HSP90 inhibitor. We find that
a quarter of the proteins show bimodal dynamics: they
rise in some cells and drop in others. This bimodality
begins about 12 h post-drug, and indicates the existence
of cell subpopulations. Most of the bimodal proteins
have dynamics that correlate with eventual cell fate:
death or survival.
The existence of cell subpopulations with different dy-
namics may explain why some cells survive and others
die in response to the drug. The proteins that rise in
correlation with cell survival may be potential drug tar-
gets to enhance HSP90i effects. In previous work two of
the bimodal protein that rose preferentially in surviving
cells, DDX5 and RFC1, were shown to increase effective-
ness of CPT upon knockdown [2]. Two additional pro-
teins were found in the present study that rose in
correlation with survival: a MAPK that lies upstream of
ERK1,2 which signals for proliferation, and a tubulin sta-
bilizing protein TBCA. Future work can test the causal
link of these proteins to survival under HSP90i.
Proteins that rose in cells that eventually die in-
clude mitosis and anti-apoptotic proteins. This result
is unexpected because one might expect death-related
proteins to rise in cells that are eventually killed ra-
ther than proteins associated with cell division and
survival. One way to understand this finding is our
observation that the cells that attempt mitosis more
than 12 h after drug addition are preferentially killed.
These cells may attempt to progress through the cell
cycle and to complete mitosis in the face of the drug
but fail to do so.
The present single cell approach also allowed us to
identify localization changes indicative of oxidative
stress. Thioredoxin and thioredoxin reductase both
move to the nucleus 20 h post drug administration [24].
Such off-target effects may be relevant in understanding
and addressing the toxicity of HSP90i drug candidates.
Similar localization changes were observed also after
camptothecin treatment [2].
Differences in cell cycle phase play a major role in cell-
cell variability. We find that cells that attempted mitosis in
the first 12 h of drug treatment were preferentially killed.
This is in contrast with camptothecin that showed no
measurable cell-cycle dependence. An advantage of the
present approach is that it can directly view mitosis events.
This non-invasive measurement avoids some of the con-
cerns associated with chemical synchronization of cells to
(See figure on previous page.)
Fig. 3 Several proteins show bimodal dynamics, increasing in some cells and decreasing in others, in a way that correlates strongly with cell
survival or death. a Most proteins show dynamics which is unimodal–all cells follow the mean, with about two-fold variation around the mean.
Shown are retromer VSP26, and the enzyme ENO1. b 25 proteins have bimodal dynamics. Some cells show a decrease in protein levels (dark
blue); other cells show an increase after 12 h (red). Shown are the oncogene DDX5 and the mitotic spindle protein STMN1. c STMN1 dynamics
correlate with cell survival or killing: cells in which STMN1 increases are preferentially killed. Surviving cells are in light blue, killed cells in red. d
Histogram of slopes of STMN1 protein accumulation in the last 10 h (slope of linear regression of protein level as a function of time). Cells with a
large slope (increase) preferentially are killed. e DDX5 dynamics correlate in an inverse way with survival or killing: cells in which DDX5 increases
preferentially survive to the end of the movie. Surviving cells are in light blue, killed cells in red. f Histogram of slopes of DDX5 protein accumulation
in the last 10 h (slope of linear regression of protein level as a function of time). Cells with a large slope (increase) preferentially survive
Fig. 4 Cells which undergo mitosis 12 h after drug treatment are
preferentially killed. Bar plot shows percentage of cells which show
morphological correlate of cell death in the 20 h movie. Cells are
binned into those that show mitosis in the first 12 h (n = 161 cells),
and those that do not (n = 120 cells). Cells are from multiple movies
with different clones. Error bars are standard errors
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study cell-cycle effects. This advantage allowed dynamic
proteomics to accurately detect cell-cycle dependent pro-
teins in previous studies [28–30].
Future work can address the origin of the subpopula-
tions found here. One possibility is that the subpopula-
tions are formed dynamically after the drug is added.
Another possibility is that subpopulations exist before the
drug treatment due to genetic mutation or a slowly revers-
ible epigenetic change [6]. Previous work on the H1299
cell line, the parental cell line for the present clones, sug-
gests that it may harbor preexisting subpopulations. For
H1299, cisplatin treatment of unsorted or stem cell
marker CD44+ cells resulted in no significant increase of
apoptotic cells compared to the untreated control, while
CD44- cells showed significant increase in apoptosis after
cisplatin treatment [31]. H1299 telomere-lengthening cor-
relates with telomerase activity, but exhibits clonal vari-
ability in telomere-lengthening and telomerase activity
[32]. Suboptimal doses of cisplatin on H1299 cells and re-
plating select for an enhanced malignant phenotype [33].
These findings are in line with the idea that H1299 in-
cludes at least two different subclones with different drug-
sensitivities.
It would be intriguing to further study the nature of
the cell subpopulations in more detail. One can ask
whether bimodal proteins go up and down in a coordi-
nated way in each cell, or whether they are uncoordin-
ated. This may require multi-color tagging of these
proteins [28]. It would be important to test other drugs
and cell lines in order to explore the generality of bimo-
dality that correlates with cell fate.
Conclusion
This study used single-cell dynamic proteomics to re-
veal sub-populations of cells that have different
protein dynamics in response to a drug within a
clonal cell line, in a way that correlates with cell sur-
vival or death. Bimodal proteins which correlate with
cell fate may be potential drug targets to enhance the
effects of therapy.
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